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Systemic sclerosis
Key messages
 ► Autologous haematopoietic stem cell transplanta-
tion (HSCT) is currently the only disease modifying 
strategy that demonstrated grade A evidence for 
improving long-term survival, prevention of organ 
worsening as well as improvement of skin and pul-
monary function in systemic sclerosis (SSc).
 ► A limited window of opportunity exists for HSCT 
treatment in SSc as severe irreversible organ in-
volvement precludes transplantation.
 ► Autologous HSCT should be considered for carefully 
selected patients with early rapidly progressive dif-
fuse SSc and a poor prognosis for survival.
 ► Risks of HSCT include, but are not limited to, early 
treatment-related mortality, gonadal failure and sec-
ondary autoimmune diseases.
AbstrAct
Three randomised controlled trials of haematopoietic stem 
cell transplantation (HSCT) in systemic sclerosis (SSc) 
demonstrated long-term survival benefits, induction of 
clinically meaningful, sustained improvement of forced 
vital capacity with improvements in skin thickening, 
vasculopathy and health-related quality of life, in contrast 
to a clinical decline in standard of care control groups. 
These benefits, however, must be weighed against the 
increased risk of transplant-related mortality. Further, 
with disease progression, severe extensive internal 
organ involvement and damage ensues, constituting an 
exclusion criterion for safety reasons, leaving a limited 
window whereby patients with SSc are eligible for HSCT. 
Although autologous HSCT offers the possibility of drug-
free remission, relapse can occur, requiring re-initiation 
of disease modifying antirheumatic drugs. HSCT is also 
associated with secondary autoimmune diseases and 
gonadal failure. HSCT should be proposed for carefully 
selected patients with early rapidly progressive diffuse 
SSc whose clinical picture portends a poor prognosis for 
survival, but yet lacks advanced organ involvement.
InTroduCTIon
Systemic sclerosis (SSc) is a rare, clinically heter-
ogeneous multisystem autoimmune disorder 
driven by inflammation, fibrosis and a microangi-
opathic vasculopathy. Internal organ involvement 
greatly impacts physical and psychological func-
tioning, impairing one’s ability to work and partic-
ipate in social activities.1 SSc disease progression 
is the leading cause of patient all-cause mortality, 
largely related to end-stage organ involve-
ment.1 2 Pulmonary and cardiac complications 
are the leading drivers of SSc-specific mortality.2 3 
Current SSc treatment recommendations 
have, until recently, focused on the manage-
ment of individual organ manifestations.4 5 
High grade evidence from randomised place-
bo-controlled clinical trials (RCTs) for poten-
tial disease modifying agents currently exists 
only for methotrexate and cyclophosphamide. 
The clinical benefit of these drugs is, however, 
limited by moderate or short-term efficacy.6–9 
Great hope anticipates several ongoing prospec-
tive phase II/III RCTs of targeted therapies in 
SSc, with results expected in 2018/2019.10 
Haematopoietic stem cell transplanta-
tion (HSCT) has been used in the treat-
ment of autoimmune disorders refractory to 
conventional immunosuppression for over 2 
decades.11 Since 2013, the yearly frequency 
of HSCT has steadily increased,12 with the 
European Society for Blood and Marrow 
Transplantation (EBMT) registering approx-
imately 2300 HSCT procedures in 2016 for 
a variety of autoimmune diseases.12 Three 
RCTs have now demonstrated clinically mean-
ingful improvement of organ involvement 
and survival in patients with SSc undergoing 
HSCT, further increasing awareness and 
interest in this complex procedure.13–15 These 
results have sparked the European League 
against Rheumatism (EULAR) to recom-
mend that HSCT be considered for patients 
with rapidly progressive SSc who are at risk 
for organ failure.4 The aim of this manuscript 
is to examine the rationale, benefits and risks 
of HSCT in SSc, predicated on the high-level 
findings produced from RCTs.
rationale
HSCT aims to non-specifically immunoab-
late aberrant self-reactive T-cells and B-cells 
via high-dose immunosuppression, with 
subsequent reconstitution of a renewed 
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and tolerant immune system by means of infusing a 
patient’s previously collected haematopoietic stem cells 
(‘transplantation’).16 Autologous HSCT (employing the 
patient’s own stem cells) is preferred over allogeneic 
HSCT (employing stem cells from a different person), 
due to autologous HSCT having a lower treatment-re-
lated mortality and lack of graft-vs-host disease, although 
sustained remissions of SSc have been observed with both 
procedures.17 18 
There are four main stages of HSCT. Mobilisation: Stem 
cells are stimulated and mobilised from the patients’ bone 
marrow using substances like granulocyte colony-stim-
ulating factor (G-CSF) and cyclophosphamide which 
causes the release of proteases with cleavage of adhesion 
molecules, facilitating the release of haematopoietic stem 
cells into the peripheral blood; however, G-CSF alone has 
been shown to be efficacious in mobilisation. Harvesting: 
subsequently these stem cells are collected from periph-
eral circulation and stored in liquid nitrogen. At this 
point, either simple apheresis or stem cell manipulation 
with selection for CD34+ can occur (or if the patient’s 
umbilical cord blood was banked it can be used to supple-
ment quantity). Though selection for and reinfusion of 
high concentration CD34+ cells may result in extended 
periods of severe immunodeficiency, such manipulation 
may prevent reinfusion of autoreactive cells. Conditioning: 
A few weeks following stem cell harvest, the majority of 
resident autoreactive T-lymphocyte and B-lymphocyte 
subsets are eliminated using high doses of cyclophospha-
mide, antithymocyte globulin (ATG) with/without total 
body irradiation (TBI). Conditioning regimens without 
TBI are predominantly lymphoablative, profoundly 
depleting lymphocytes, while preserving cyclophospha-
mide-resistant myelogenous stem cells, whereas regimens 
employing TBI are also myeloablative. Transplantation: 
shortly after conditioning, stem cells are thawed and rein-
fused. Endogenous haematopoiesis could reconstitute 
even without transplantation; however, stem cell grafting 
shortens the period of pancytopenia, allowing adaptive 
immunity to be rebuilt through clonal expansion of the 
remaining immunocompetent cells, formation of new 
non-autoreactive cells (thymopoiesis) and graft-derived 
regulatory T-cells.16 Complete elimination of autoreac-
tive T-cells is impossible, but through clonal expansion 
they become outnumbered by the newer tolerant clones, 
with relatively few patients with autoimmune diseases 
relapsing despite persistent post-transplant autoreactive 
clones.19 
Benefits of autologous HSCT
Multiple cohorts20–24 and a case control study25 suggested 
beneficial effects of autologous HSCT in patients with 
rapidly progressive SSc. The majority of patients treated 
with HSCT had the early rapidly progressive diffuse 
cutaneous form of SSc, without yet having progressed to 
severe internal organ involvement.
In these SSc cohorts, HSCT predominantly induced 
a medically significant improvement of the modified 
Rodnan skin score (mRSS),17 20 21 26 27 forced vital capacity 
(FVC),26 extent of fibrosis on chest CT28 as well as both 
the physical and mental components health-related 
quality of life (HRQoL).26 27 Furthermore, HSCT rapidly 
improved skin fibrosis beyond that of the control group20 
and unlike conventional treatment with cyclophospha-
mide29 reduced capillary loss, both of which are hallmark 
characteristics in the pathogenesis of SSc.29–31 
Three months after the procedure, the mRSS had 
regressed from a mean of 27 to 5 in one cohort17 and 
from 24.1 before transplantation to 16.5 by 6 months and 
12.9 by 12 months in another cohort..20 As these data 
were uncontrolled, the improvement of mRSS needs to 
be interpreted with caution.
SSc relapses after successful HSCT do occur. In an 
analysis of 57 patients with SSc  who had undergone 
autologous HSCT, partial or complete responses were 
seen in 92% of patients, but 35% of patients relapsed 
within 10 months.32 The EBMT cohort calculated a 63% 
3-year progression-free survival of patients with SSc after 
transplantation, and the overall survival after 3 years 
was 80%.22 Multivariate analysis indicated that progres-
sion-free survival rates were higher in younger than 
in older patients.22 In US cohorts, the 5-year progres-
sion-free survival was reported between 64% and 70% 
and the overall survival between 64% and 78%.13 20 
Uncontrolled clinical studies, including cohort studies, 
are difficult to interpret in SSc because the natural disease 
course evolves with regression of skin fibrosis and overall 
disease activity over time. Thus, RCTs are of key impor-
tance to substantiate efficacy of a treatment regimen 
in SSc. Three RCTs of autologous HSCT have been 
performed. All three trials included patients with early 
forms of diffuse SSc and high risk of death from or devel-
oping internal organ involvement. Patients with severe 
internal organ involvement were excluded (table 1).
The first RCT was the American Scleroderma Stem 
cell versus Immune Suppression Trial (ASSIST), a phase 
II trial comparing autologous non-myeloablative HSCT 
with monthly intravenous cyclophosphamide therapy.13 
After randomisation, 10 patients underwent autologous 
HSCT, while 9 patients in the control group received 6 
monthly pulses of cyclophosphamide. At month 12, all 
patients treated with HSCT demonstrated significant 
improvement (defined as a>25% decrease in mRSS for 
those with initial mRSS >14 or a>10% increase in FVC), 
while 8 of the 9 controls exhibited disease progression 
(defined as >25% increase in mRSS or >10% decrease 
in FVC). Of the eight controls with an unsatisfactory 
response, seven crossed over to the transplant arm, all 
of whom demonstrated improvement. At 6 months, the 
annualised rate of change from pretreatment FVC was 
34% in patients undergoing HSCT, compared with –10% 
in controls (p=0.002), at 12 months the rates were 15% 
and –9%, respectively (p=0.006). Twelve months following 
randomisation, the mean mRSS had decreased by almost 
half in the transplant group, but increased in the control 
group. Similarly, significant and clinically meaningful 
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Table 1  Comparison of patient selection, treatment modality and outcomes among three randomised trials investigating 
HSCT in SSc.
ASSIST13 ASTIS14 SCOT15 
Patient number 19 156 75
Inclusion criteria <60 years of age 18–65 years of age 18–69 years of age
Diffuse SSc Diffuse SSc Diffuse SSc
mRSS≥15 mRSS≥15 mRSS≥16
Disease duration ≤4 years Disease duration ≤4 years Disease duration ≤4 years
Internal organ involvement Internal organ involvement Internal organ involvement
Exclusion criteria Mean PAP>25 mm Hg or 
PAPsys>40 mm Hg
Mean PAP>50 mm Hg Mean PAP>30 mm Hg
LVEF<40% LVEF<45% LVEF<50%
– – FVC<45% predicted
DLCO<40% predicted
Creatinine >177 umol/L Creatinine clearance <40 mL/
min
Creatinine clearance <40 mL/
min
Cyclophosphamide>6 
intravenous courses
Cyclophosphamide cumulative 
intravenous dose >5 g or >3 
months oral
Cyclophosphamide cumulative 
intravenous dose >3 g/m2 or 
>4 months oral or >6 months 
intravenous
– – Active GAVE
Mobilisation Cyclophosphamide 2 g/m2, 
G-CSF
Cyclophosphamide 4 g/m2, 
G-CSF
G-CSF only
Conditioning Cyclophosphamide (200 mg/
kg), rabbit ATG
Cyclophosphamide (200 mg/
kg), rabbit ATG
Cyclophosphamide (120 mg/
kg), equine ATG
Total body irradiation No No Yes (800 cGy, lung and kidney 
shielding)
Stem cell manipulation None CD34+ selection CD34+ selection
Comparator arm Cyclophosphamide 6 monthly 
intravenous courses (1000 mg 
/m2)
Cyclophosphamide 12 
monthly intravenous courses 
(750 mg/m2).
Cyclophosphamide 12 
monthly intravenous courses 
(750 mg/m2).
Primary outcome measure >25% decrease in mRSS, or 
>10% increase in FVC at 12 
months
Survival without new onset 
heart, lung or kidney failure
Global Rank Composite Score 
at month 54
Follow-up 2.6 years (mean) 5.8 years (median) Up to 4.5 years
12-month treatment-related 
mortality in comparator arm
0 (0%) 0 (0%) 0 (0%)
12-month transplant-related 
mortality
0 (0%) 8 (10.1%) 1 (3%)
ASSIST, American Scleroderma Stem cell versus Immune Suppression Trial; ASTIS, Autologous Stem cell Transplantation International 
Scleroderma Trial; ATG, antithymocyte globulin; FVC, forced vital capacity; GAVE, gastric antral vascular ectasia; G-CSF, granulocyte-colony 
stimulating factor; LVEF, left ventricular ejection fraction; mRSS, modified Rodnan skin score; PAP, pulmonary arterial pressure; SCOT, The 
Scleroderma Cyclophosphamide Or Transplantation; SSc, systemic sclerosis.
improvement of HRQoL occurred in the HSCT group 
with a change in the total 36-item Short Form Health 
Survey (SF-36) score from 39 to 56 during the 12 months 
after transplantation, but deteriorated significantly from 
50 to 40 in the control arm. After a mean follow-up of 2.6 
years, 15 of the 17 patients undergoing HSCT maintained 
persistent improvement in mRSS and FVC. There were 
no deaths in either arm of the ASSIST trial. The study had 
limitations: due to the small sample size, baseline data 
were not matched, for example, higher baseline mRSS 
was reported in the treatment group favouring sponta-
neous regression to the mean. It was also a one centre 
trial not necessarily reflecting real-world circumstances.
These limitations were addressed in the second trial, 
the Autologous Stem cell Transplantation International 
Scleroderma Trial (ASTIS) trial.14 This first phase III trial 
in SSc randomised a total of 156 patients (mean age 44 
years) to receive autologous HSCT or 12-monthly pulses 
of intravenous cyclophosphamide. In the transplant 
arm of ASTIS, stem cells were mobilised with a total of 
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4 g/m2 of intravenous cyclophosphamide and G-CSF. 
After conditioning with 200 mg/kg of intravenous cyclo-
phosphamide, administered with hyperhydration and 
rabbit ATG, CD34-selected stem cells were reinfused 
(table 1). The majority of the patients in ASTIS (87%) 
had lung involvement; the mean mRSS at entry was 25, 
and 10% had severe skin involvement without internal 
organ involvement. The primary endpoint was event-
free survival (EFS), defined as the time in days from 
randomisation until the occurrence of death or major 
organ failure. In the group undergoing HSCT, there 
were better event-free and overall survival rates. During 
a median follow-up of 5.8 years, 19 deaths and 3 irre-
versible organ failures occurred in the HSCT group, 
while in the control group 23 deaths and 8 irreversible 
organ failures were recorded. In the control arm, an 
additional seven patients died subsequent to irreversible 
organ failure. Secondary endpoints of ASTIS, defined as 
the change in mRSS in the first 2 years, Health Assess-
ment Questionnaire (HAQ), EuroQoL or SF-36 scores 
were also significantly better in the HSCT group. No 
significant changes were seen for left ventricular ejec-
tion fraction or diffusing capacity of the lung for carbon 
monoxide (DLCO). However, a 6.3% increase in FVC 
and a modest but statistically significant decrease in 
creatinine clearance was seen in the HSCT group. In 
ASTIS, HSCT was associated with a relatively high treat-
ment-related mortality in the first year after transplanta-
tion, higher than that in the other RCTs. In the first year 
following randomisation, there were 11 deaths (13.9%) 
in the HSCT group vs 7 (9.1%) in the cyclophosphamide 
group. Eight of the 11 deaths (10%) in the HSCT group 
were treatment-related, and no death was attributed 
to treatment in the cyclophosphamide control arm. In 
subsequent years, the high treatment-related mortality 
observed in the first year post-HSCT was outweighed by a 
significant long-term all-cause mortality benefit observed 
in the HSCT arm. Between 12 and 24 months following 
HSCT, SSc relapsed in 22.4% of patients, but significantly 
fewer patients in the HSCT group as compared with the 
control group required immunosuppressive medication 
(22% vs 44%).
The Scleroderma Cyclophosphamide Or Transplan-
tation (SCOT) trial is the third and most recent RCT 
examining the effects of HSCT in SSc.15 Like the ASSIST 
and ASTIS trials, SCOT compared autologous HSCT with 
monthly cyclophosphamide pulses; the conditioning 
regimen, however, differed in that it added TBI. The ratio-
nale for irradiation is based in part on the observed higher 
effectiveness of the transplantation procedure with addi-
tion of irradiation in animal models.33 The SCOT trial 
also differed in that it did not employ cyclophosphamide 
for mobilisation and used less cyclophosphamide during 
conditioning compared with the previous trials (table 1). 
Seventy-five patients with SSc (mean age 46 years) were 
randomised, with 97% having pulmonary involvement, 
characterised by a mean baseline FVC and DLCO of 74% 
and 53% predicted, respectively and a baseline mRSS of 
30. Fifty-nine patients had received disease modifying 
antirheumatic medication prior to randomisation. The 
primary endpoint of the SCOT trial was a Global Rank 
Composite Score (GRCS), a tool that simultaneously 
accounts for multiple disease manifestations based on 
the following hierarchy of outcomes: death, EFS, FVC, 
HAQ-Disability Index (HAQ-DI) and mRSS. The GRCS 
does not measure disease activity or severity but compares 
patients by means of hierarchical ordered outcomes. The 
GRCS score at 54 months showed superiority of HSCT 
over cyclophosphamide. Superiority of HSCT was also 
demonstrated for all-cause mortality; of the 36 patients 
randomised to receive HSCT, 3 patients had died by 
month 54 and 1 death was considered treatment-re-
lated, while of the 39 patients in the cyclophosphamide 
arm, 11 died and no death was considered treatment-re-
lated. HSCT was also superior to cyclophosphamide in 
terms of mRSS evolution, change in FVC and HRQoL 
measures (HAQ-DI and SF-36). No pulmonary arterial 
hypertension or congestive heart failure was observed in 
the HSCT arm 54 months after HSCT, significantly less 
than the 15% and 12% of cases, respectively, observed 
in the cyclophosphamide arm. In the HSCT arm, 9% of 
participants required disease modifying antirheumatic 
drugs (DMARDs) post-transplantation, significantly less 
than the 44% of patients in the cyclophosphamide arm. 
There were similar rates of infections (of any grade) in 
both groups; however, the rate of grade 3 infections or 
higher per person-year was nominally higher in the trans-
plantation group than in the cyclophosphamide group 
(0.21 vs 0.13 p=0.09). One patient in the HSCT arm and 
five patients in the cyclophosphamide arm experienced 
renal crisis during the 54 months follow-up period. The 
54 months post-treatment EFS was 72.2% in HSCT group 
and 48.7% in control group. The overall survival of autol-
ogous HSCT-treated patients was 91% and 77% in the 
control patients.
In summary, all three RCTs reported significant 
improvement in organ specific manifestations, such as 
skin and pulmonary function, and HRQoL. Despite an 
elevated risk of treatment-related mortality early after the 
intervention, there were significant long-term survival 
advantages following HSCT in both of the two RCTs 
investigating long term survival.
risks of HSCT
The benefits of any treatment procedure need to be 
weighed against its risks. The mortality associated with 
HSCT appears to be significant in the RCTs, especially in 
the ASTIS trial. There was no centre effect of mortality 
in ASTIS.14 The small sample size of the ASSIST trial and 
the selection of patients may explain the survival of all 
patients in this trial; similarly, the smaller sample size in 
SCOT than in ASTIS may contribute to differences in 
mortality. Further, in ASTIS, the solitary variable shown 
in a posthoc analysis to impact differences in EFS and 
overall survival was smoking status, as in former/current 
smokers HSCT lacked the benefit demonstrated in the 
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never-smoking subjects. Similarly, SCOT data also suggest 
that in former and current smokers, transplantation had 
no advantage over cyclophosphamide.15 
The EBMT analysed mortality after autologous HSCT 
for severe autoimmune disease from 1996 to December 
2007 and reported a 5% mortality by day 100 following 
transplantation.22 In 175 patients with SSc transplanted 
from 1996 until 2007, the mortality was slightly higher 
(6%) than in other autoimmune diseases, possibly due 
to the severity of SSc and the presence of major organ 
dysfunction in transplanted patients with SSc.22 26 The 
causes of death included SSc recurrence (23 patients), 
transplant-related mortality (12 patients), cardiotoxicity 
(1 patient), haemorrhage and secondary malignancies (2 
patients each) as well as infections (4 patients).22 Careful 
patient selection is crucial in order to reduce treatment-re-
lated mortality. SSc has unique and complex cardiac 
manifestations and cyclophosphamide is associated with 
cardiotoxicity.26 A comprehensive pretransplant cardiac 
assessment is therefore recommended even in patients 
without cardiac symptoms and typically includes trans-
thoracic echocardiography, cardiac MRI with gadolinium 
contrast, a Holter ECG and right heart catheterisation 
(RHC).34 A 6 min walk test is also recommended.26 Some 
authors and the EBMT suggest an intravascular fluid 
challenge during RHC (10 mL saline/ kg body weight, 
given intravenous over 10 min).26 34 A mean pulmonary 
arterial pressure (PAP)>30 mm Hg or a systolic PAP>40 
mm Hg after fluid challenge could detect patients with 
subclinical heart involvement related to cardiomyopa-
thic restriction seen in SSc, who might fluid-sensitive and 
develop complications during hypervolemic interven-
tions often necessary during the conditioning regimen 
or should systemic infection develop.26 34 
HSCT can induce gonadal failure in both sexes. In 
men, azoospermia occurs in the majority of patients 
but in most cases testosterone levels remain within the 
normal limits.35 In premenopausal women, the condi-
tioning regimen results in transitory or permanent amen-
orrhoea with concomitant infertility and menopausal 
symptoms. Before mobilisation and HSCT, consideration 
should therefore be given to infertility in both sexes 
(semen, oocyte or embryo cryopreservation as appro-
priate). Hormone replacement therapy should be started 
with gonadal failure.36 TBI used as part of the condi-
tioning regimen plays a central role in post-transplanta-
tion infertility,35 but in regimen without TBI a substantial 
percentage of women have been described to remain 
fertile, give birth to healthy babies and without increased 
occurrence of miscarriages.37 The decline of post-HSCT 
rates of sexual activity and diminished interest/libido 
and adequate function is possibly related to preparation 
regimen using alkylating agents and TBI which impacts 
on the function of the hypothalamic-pituitary-gonadal 
axis function. Sexual dysfunction may persist long term 
in both sexes despite some recovery after the 6 months 
post-transplant nadir.38 
Regarding renal protection and outcome, life-long 
post-transplant therapy with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers is 
recommended to prevent renal crisis.26 39 However, it is 
unclear whether prophylactic ACE inhibition leads to 
more severe outcomes of renal crisis.40 
In addition to better understanding frequency of 
and predisposition to relapse/graft failure, long-term 
follow-up of transplanted patients with SSc will be 
important to better characterise and quantify known 
late sequelae of HSCT, such as secondary autoimmune 
diseases and secondary malignancies.41 Five years after 
autologous HSCT for autoimmune diseases, the cumu-
lative incidence of secondary autoimmune diseases was 
as high as 9.8%.42 Intriguingly, the ‘new’ autoimmunity 
developing after transplantation appeared to be mainly 
antibody-associated and organ-speciﬁc.43 44 Lupus erythe-
matosus as primary autoimmune disease and ATG use 
were risk factors for the occurrence of secondary auto-
immune diseases, whereas the presumed beneficial role 
of CD34+ graft selection is controversial.42 44 The attenu-
ation of immunological memory in the B cell compart-
ment after autologous HSCT also implies that patients 
must be reimmunised.45 
Because of the high risk of treatment related side 
effects and of early treatment related mortality, the new 
EULAR treatment recommendations advice for careful 
selection of patients with SSc for HSCT. It is also high-
lighted that the experience of the medical team are of 
key importance.4 
research agenda
Head-to-head studies have not been carried out to 
determine the optimal stem cell collection and condi-
tioning procedure in the HSCT regimen. It is unclear, 
if the ex vivo CD34+ selection of stem cells truly confers 
a benefit over non-selected cells.16 The potential risk of 
reinfusing autoreactive T-cells with non-selected grafts 
may be outweighed by reduced numbers of transplanted 
cells and increased immunosuppression in patients 
receiving CD34+ grafts.46 Reducing cyclophosphamide 
doses may on the one hand decrease toxicity in terms of 
infections, but on the other hand decrease the efficacy 
of HSCT. Cyclophosphamide may also induce haemor-
rhagic cystitis. Patients should receive urometixan.36 It is 
however unclear if the hyperhydration recommended for 
the prophylaxis of haemorrhagic cystitis36 may contribute 
to transplant related mortality in patients with decreased 
cardiac compliance.
Animal studies indicate that a conditioning regimen 
that adds irradiation to cyclophosphamide may provide 
a better control of autoimmune diseases.33 As the SCOT 
trial has inclusion criteria and a control group similar 
to those in the ASTIS trial, a comparative analysis with 
regard to the use and not-use of irradiation during 
conditioning may be possible. In the SCOT trial, only 
9% of transplant recipients had initiated DMARDs by 
24 months, as compared with 22% in the ASTIS trial, 
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suggesting better SSc control with myeloablative HSCT. 
Adding TBI, however, also implies an excess risk of 
cancers over a lifetime.
With regard to the known cardiotoxicity of high-dose 
cyclophosphamide used during the conditioning step, it 
is unclear which patients are at particular risk and which 
conditioning is best. In order to diminish cyclophospha-
mide requirements, conditioning regimens have been 
used that employ thiotepa, a non-cardiotoxic alkylating 
agent,47 but comparative studies are lacking.
It is also currently vague, if other agents used during 
the HSCT procedure put specific patients with SSc at risk. 
G-CSF could induce disease flares if administered alone, 
although the combination with cyclophosphamide in the 
mobilisation step effect may prevent flares and improve 
stem cell yields.36 ATG is associated with a risk of allergic 
reactions and its profound immunosuppression increases 
the risk of acquired and reactivated infections.36
To address the issue of disease relapse after successful 
transplantation, the Scleroderma Treatment with 
Autologous Transplant (STAT) trial ( ClinicalTrials. gov 
identifier: NCT01413100) is currently recruiting. The 
conditioning regimen of STAT uses no CD34+ selection 
after mobilisation of stem cells and apheresis and the 
conditioning regimen consists of cyclophosphamide and 
ATG, but without TBI. In the STAT trial, open label myco-
phenolate mofetil is added approximately 2–3 months 
post-transplant after the stem cells have ‘engrafted’ and 
mycophenolate mofetil is maintained for 2 years. The 
primary outcome of this single group trial is defined as 
EFS 5 years after transplantation.
Last, developing more specific and validated criteria 
for patient selection is ongoing. It is currently unclear 
which cardiac screening is optimal and which cardiac 
parameters are predictive of an increased transplant 
related cardiac mortality. Hopefully, analysis of past and 
future studies will help clarify risk stratifications incor-
porating factors of age, functional performance status, 
rate of disease progression, parameters of SSc damage, 
smoking and cardiac compliance.
Summary and ConCluSIon
Autologous HSCT is the first therapeutic intervention 
with proven survival advantages in a subgroup of patients 
with SSc. In addition to improving survival, three RCTs 
demonstrated significant improvement of organ func-
tion, vasculopathy, skin involvement and HRQoL. 
HSCT has induced clinically meaningful and sustained 
improvements of lung function despite decline in 
control groups. Autologous HSCT is currently the only 
disease modifying strategy with high-level evidence for 
improving SSc survival, prevention of organ worsening 
and improvement of pulmonary function. Although 
autologous HSCT offers the possibility of drug-free 
remission, patients may experience a relapse requiring 
disease modifying antirheumatic drugs. HSCT is also 
associated with secondary autoimmune diseases and 
gonadal failure. The benefits of HSCT must be balanced 
against the increased risk of transplant-related mortality 
in the first year. A patient with early SSc, internal organ 
involvement and concomitant poor prognostic factors 
has a limited window within which they are eligible for 
HSCT. As the disease progresses, severe internal organ 
damage ensues and constitutes an exclusion criterion for 
the procedure. The EULAR treatment recommendations 
indicate HSCT for carefully selected patients with rapidly 
progressive SSc at risk of organ failure. HSCT should be 
performed in centres experienced in HSCT. More specif-
ically, we recommend considering HSCT in patients 
with early, progressive diffuse SSc with strongly reduced 
survival as predicted by validated tools, yet without severe 
organ involvement.48 
Contributors UAw wrote the first draft of the manuscript. All coauthors refined 
this first version and approved the final version.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; externally peer reviewed.
data sharing statement No additional data are available.
open access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY 4.0) license, which permits 
others to distribute, remix, adapt, build upon this work non-commercially, and 
license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by/ 4.0
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. Jaeger VK, Distler O, Maurer B, et al. Functional disability and 
its predictors in systemic sclerosis: a study from the DeSScipher 
project within the EUSTAR group. Rheumatology 2018;57:441–50.
 2. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for 
death in systemic sclerosis: a study from the EULAR Scleroderma 
Trials and Research (EUSTAR) database. Ann Rheum Dis 
2010;69:1809–15.
 3. Elhai M, Meune C, Boubaya M, et al. Mapping and 
predicting mortality from systemic sclerosis. Ann Rheum Dis 
2017;76:1897–905.
 4. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR 
recommendations for the treatment of systemic sclerosis. Ann 
Rheum Dis 2017;76:1327–39.
 5. Khanna D, Furst DE, Clements PJ, et al. Oral cyclophosphamide 
for active scleroderma lung disease: a decision analysis. Med Decis 
Making 2008;28:926–37.
 6. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison 
of methotrexate with placebo in the treatment of systemic sclerosis: 
a 24 week randomized double-blind trial, followed by a 24 week 
observational trial. Br J Rheumatol 1996;35:364–72.
 7. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial 
of methotrexate versus placebo in early diffuse scleroderma. Arthritis 
Rheum 2001;44:1351–8.
 8. Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide 
on pulmonary function in patients with scleroderma and interstitial 
lung disease: a systematic review and meta-analysis of randomized 
controlled trials and observational prospective cohort studies. 
Arthritis Res Ther 2008;10:R124.
 9. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of 
subcutaneous tocilizumab in adults with systemic sclerosis 
(faSScinate): a phase 2, randomised, controlled trial. Lancet 
2016;387:2630–40.
 10. Khanna D, Distler JHW, Sandner P. Emerging treatment strategies for 
systemic sclerosis. J Scleroderma Relat Disord 2016;1:186–93.
 o
n
 21 August 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000533 on 17 June 2018. Downloaded from
 
7walker UA, et al. RMD Open 2018;4:e000533. doi:10.1136/rmdopen-2017-000533
Systemic sclerosis
 11. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous 
stem cell transplantation in systemic sclerosis: procedure 
related mortality and impact on skin disease. Ann Rheum Dis 
2001;60:577–84.
 12. Snowden J. Autoimmune diseases working party. European society 
of blood and marrow transplantation - annual report. 2016.
 13. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative 
haemopoietic stem-cell transplantation compared with pulse 
cyclophosphamide once per month for systemic sclerosis (ASSIST): 
an open-label, randomised phase 2 trial. Lancet 2011;378:498–506.
 14. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic 
stem cell transplantation vs intravenous pulse cyclophosphamide 
in diffuse cutaneous systemic sclerosis: a randomized clinical trial. 
JAMA 2014;311:2490–8.
 15. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative 
Autologous Stem-Cell Transplantation for Severe Scleroderma. N 
Engl J Med 2018;378:35–47.
 16. Swart JF, Delemarre EM, van Wijk F, et al. Haematopoietic stem 
cell transplantation for autoimmune diseases. Nat Rev Rheumatol 
2017;13:244–56.
 17. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow 
transplantation in patients with severe systemic sclerosis: resolution 
of dermal fibrosis. Arthritis Rheum 2006;54:1982–6.
 18. Loh Y, Oyama Y, Statkute L, et al. Non-myeloablative allogeneic 
hematopoietic stem cell transplantation for severe systemic 
sclerosis: graft-versus-autoimmunity without graft-versus-host 
disease? Bone Marrow Transplant 2007;39:435–7.
 19. Sykes M, Nikolic B. Treatment of severe autoimmune disease by 
stem-cell transplantation. Nature 2005;435:620–7.
 20. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose 
immunosuppressive therapy and autologous hematopoietic cell 
transplantation for severe systemic sclerosis: long-term follow-up of 
the US multicenter pilot study. Blood 2007;110:1388–96.
 21. Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous 
stem cell transplantation for systemic sclerosis - a single-center 
longterm experience in 26 patients with severe organ manifestations. 
J Rheumatol 2012;39:269–75.
 22. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic 
stem cell transplantation for autoimmune diseases: an observational 
study on 12 years' experience from the European group for blood 
and marrow transplantation working party on autoimmune diseases. 
Haematologica 2010;95:284–92.
 23. Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term 
follow-up results after autologous haematopoietic stem cell 
transplantation for severe systemic sclerosis. Ann Rheum Dis 
2008;67:98–104.
 24. Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative 
hematopoietic stem cell transplantation in patients with systemic 
sclerosis. Bone Marrow Transplant 2007;40:549–55.
 25. Del Papa N, Onida F, Zaccara E, et al. Autologous hematopoietic 
stem cell transplantation has better outcomes than conventional 
therapies in patients with rapidly progressive systemic sclerosis. 
Bone Marrow Transplant 2017;52:53–8.
 26. Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and 
treatment-related mortality after non-myeloablative haemopoietic 
stem-cell transplantation with unselected autologous peripheral 
blood for patients with systemic sclerosis: a retrospective analysis. 
Lancet 2013;381:1116–24.
 27. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose 
immunosuppressive therapy for severe systemic sclerosis: initial 
outcomes. Blood 2002;100:1602–10.
 28. Launay D, Marjanovic Z, de Bazelaire C, et al. Autologous 
hematopoietic stem cell transplant in systemic sclerosis: quantitative 
high resolution computed tomography of the chest scoring. J 
Rheumatol 2009;36:1460–3.
 29. Miniati I, Guiducci S, Conforti ML, et al. Autologous stem cell 
transplantation improves microcirculation in systemic sclerosis. Ann 
Rheum Dis 2009;68:94–8.
 30. Aschwanden M, Daikeler T, Jaeger KA, et al. Rapid improvement 
of nailfold capillaroscopy after intense immunosuppression for 
systemic sclerosis and mixed connective tissue disease. Ann Rheum 
Dis 2008;67:1057–9.
 31. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration 
in scleroderma: stem cell therapy reverses phenotype? PLoS One 
2008;3:e1452.
 32. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell 
transplantation in the treatment of systemic sclerosis: report from 
the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974–81.
 33. van Bekkum DW. Effectiveness and risks of total body irradiation 
for conditioning in the treatment of autoimmune disease with 
autologous bone marrow transplantation. Rheumatology 
1999;38:757–61.
 34. Farge D, Burt RK, Oliveira MC, et al. Cardiopulmonary assessment 
of patients with systemic sclerosis for hematopoietic stem cell 
transplantation: recommendations from the European society 
for blood and marrow transplantation autoimmune diseases 
working party and collaborating partners. Bone Marrow Transplant 
2017;52:1495–.
 35. Rovó A, Tichelli A, Passweg JR, et al. Spermatogenesis in 
long-term survivors after allogeneic hematopoietic stem cell 
transplantation is associated with age, time interval since 
transplantation, and apparently absence of chronic GvHD. Blood 
2006;108:1100–5.
 36. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in 
severe autoimmune diseases: updated guidelines of the European 
group for blood and marrow transplantation. Bone Marrow 
Transplant 2012;47:770–90.
 37. Massenkeil G, Alexander T, Rosen O, et al. Long-term follow-
up of fertility and pregnancy in autoimmune diseases after 
autologous haematopoietic stem cell transplantation. Rheumatol Int 
2016;36:1563–8.
 38. Syrjala KL, Kurland BF, Abrams JR, et al. Sexual function changes 
during the 5 years after high-dose treatment and hematopoietic cell 
transplantation for malignancy, with case-matched controls at 5 
years. Blood 2008;111:989–96.
 39. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell 
transplantation for poor-prognosis systemic sclerosis. Rheumatology 
2015;54:2126–33.
 40. Hudson M, Baron M, Tatibouet S, et al. Exposure to ACE inhibitors 
prior to the onset of scleroderma renal crisis-results from the 
International scleroderma renal crisis survey. Semin Arthritis Rheum 
2014;43:666–72.
 41. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone 
marrow transplantation. N Engl J Med 1997;336:897–904.
 42. Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune 
diseases occurring after HSCT for an autoimmune disease: a 
retrospective study of the EBMT autoimmune disease working party. 
Blood 2011;118:1693–8.
 43. Holbro A, Abinun M, Daikeler T. Management of autoimmune 
diseases after haematopoietic stem cell transplantation. Br J 
Haematol 2012;157:281–90.
 44. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary 
autoimmune disorder after hematopoietic stem cell transplantation 
for autoimmune diseases: role of conditioning regimen used. Blood 
2007;109:2643–2548.
 45. Singhal S, Mehta J. Reimmunization after blood or marrow stem cell 
transplantation. Bone Marrow Transplant 1999;23:637–46.
 46. Oliveira MC, Labopin M, Henes J, et al. Does ex vivo CD34+ positive 
selection influence outcome after autologous hematopoietic stem 
cell transplantation in systemic sclerosis patients? Bone Marrow 
Transplant 2016;51:501–5.
 47. Henes JC, Koetter I, Horger M, et al. Autologous stem cell 
transplantation with thiotepa-based conditioning in patients with 
systemic sclerosis and cardiac manifestations. Rheumatology 
2014;53:919–22.
 48. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical 
prediction of 5-year survival in systemic sclerosis: validation of 
a simple prognostic model in EUSTAR centres. Ann Rheum Dis 
2011;70:1788–92.
 o
n
 21 August 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000533 on 17 June 2018. Downloaded from
 
